Table 1.

Chronology of major discoveries/findings related to amantadine

Year	Discovery description	References
1963	First description of amantadine as medication—antiviral activity	Gerzon et al. (1963)
1966	Amantadine (Symmetrel) by E. I. du Pont de Nemours & Company and approved by FDA in the USA for prevention of influenza A2	Hubsher et al. (2012) and Maugh (1979)
1969	First description of antiparkinsonian activity based on case observation (1968) by woman taking amantadine for viral infection	Schwab et al. (1969)
1970	Registered by Merz Pharmaceuticals as PK-Merz (amantadine sulfate) for the treatment of Parkinson’s disease, vigilance and neuralgia in herpes zoster	Zimmermann (1997)
1971	Effect in tardive dyskinesia	Crane (1971)
1971	Effect on chorea in Huntington's disease	Scotti and Spinnler (1971)
1073	Effect in akinetic crisis and akinetic end stages of patients with Parkinson’s disease	Danielczyk (1973)
1973	Amantadine hydrochloride (Symmetrel) registered as treatment for Parkinson’s disease	Hubsher et al. (2012) and Maugh (1979)
1981	Anti-tremor activity	Manyam (1981)
1989	First report of NMDA receptor binding by amantadine	Kornhuber et al. (1989)
1989	Utility in traumatic brain injury (TBI)	Gualtieri et al. (1989)
1991	First demonstration of NMDA receptor antagonism by amantadine	Kornhuber et al. (1991)
1993	Binding to sigma receptors	Kornhuber et al. (1993)
1997	Effect in l-DOPA-induced dyskinesia	Rajput et al. (1997)
2020	Approval of Gocovri (ADS-1502, Adamas Pharma) for treatment of DOPA-induced dyskinesia	Adamas (2020)